/HTSUF

HTSUF Stock - Hisamitsu Pharmaceutical Co., Inc.

Q: What is the analyst price target for HTSUF?

Analyst price target information is not currently available for HTSUF.

Q: What is HTSUF's market cap?

Market capitalization information is not currently available for HTSUF.

Healthcare|Drug Manufacturers - Specialty & Generic|OTC

$29.00+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $31.90

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for HTSUF

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2021

FY2022

FY2023

FY2024

FY2025

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.15

52W High$32.30

52W Low$24.56

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$156.01B	$141.71B	$128.33B	$120.19B	$114.51B
Gross Profit	$91.20B	$78.97B	$72.70B	$70.07B	$69.17B
Gross Margin	58.5%	55.7%	56.7%	58.3%	60.4%
Operating Income	$18.89B	$13.17B	$11.60B	$9.34B	$10.67B
Net Income	$21.76B	$13.97B	$11.74B	$9.66B	$9.25B
Net Margin	13.9%	9.9%	9.1%	8.0%	8.1%
EPS	$295.57	$181.61	$148.00	$118.92	$113.21

Company Overview

Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals, quasi-drugs, and medical devices in Japan. The company provides external pain relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; and BUTENALOCK, a remedy for athlete's foot, as well as ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, transdermal analgesic anti-inflammatory drug; patches for female hormone, asthma treatment, and treatment for overactive bladders. In addition, the company manufactures and sells drugs under MOHRUS TAPE, MOHRUS PAP XR, FENTOS Tapes, NEOXY Tapes, Abstral, ALLESAGA Tapes, HARUROPI Tapes, and MENOAID Combipatch. Further, it provides HFT-290, a transdermal patch for cancer pain. The company sells its products in the United States and Asia. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.

Visit Website

Earnings History & Surprises

HTSUF

Beat Rate

80%

Last 5 quarters

Avg Surprise

+2393.3%

EPS vs Estimate

Beats / Misses

4/1

Last 12 quarters

Latest EPS

$0.42

Q4 2025

EPS Surprise History

Q1 24

No data

Q2 24

No data

Q3 24

+46.4%

$0.41vs$0.28

Q4 24

No data

Q1 25

No data

Q2 25

No data

Q3 25

-48.9%

$0.24vs$0.48

Q4 25

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	Apr 8, 2026	—	—	—	—
Q1 2026	Jan 8, 2026	—	—	—	—
Q4 2025	Oct 9, 2025	—	$0.42	—	—
Q3 2025	Jul 10, 2025	$0.48	$0.24	-48.9%	✗ MISS
Q2 2025	Apr 9, 2025	—	$0.73	—	—
Q1 2025	Jan 9, 2025	—	$0.42	—	—
Q4 2024	Oct 10, 2024	—	$0.40	—	—
Q3 2024	Jul 11, 2024	$0.28	$0.41	+46.4%	✓ BEAT
Q2 2024	Apr 11, 2024	—	$0.16	—	—
Q1 2024	Jan 11, 2024	—	$0.33	—	—
Q3 2023	Aug 30, 2023	—	$0.38	—	—
Q2 2023	May 31, 2023	$0.14	$0.37	+168.2%	✓ BEAT
Q1 2023	Feb 28, 2023	—	$0.21	—	—
Q1 2023	Jan 12, 2023	—	$37.88	—	—
Q4 2022	Oct 12, 2022	—	$61.11	—	—
Q3 2022	Jul 7, 2022	$0.17	$20.45	+11761.9%	✓ BEAT
Q2 2022	Apr 7, 2022	—	$43.08	—	—
Q1 2022	Jan 13, 2022	—	$14.91	—	—
Q4 2021	Oct 14, 2021	—	$32.30	—	—
Q3 2021	Jul 8, 2021	$20.80	$28.91	+39.0%	✓ BEAT

Frequently Asked Questions about HTSUF

What is HTSUF's current stock price?

Hisamitsu Pharmaceutical Co., Inc. (HTSUF) is currently trading at $29.00 per share. The stock has moved +0.00% today.

What is the analyst price target for HTSUF?

No analyst price targets are currently available for this stock.

What sector is Hisamitsu Pharmaceutical Co., Inc. in?

Hisamitsu Pharmaceutical Co., Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the OTC exchange.

What is HTSUF's market cap?

Hisamitsu Pharmaceutical Co., Inc. has a market capitalization of $2.11 billion, making it a mid-cap company.

Does HTSUF pay dividends?

No, Hisamitsu Pharmaceutical Co., Inc. does not currently pay a dividend to shareholders.